Exploring One Medicine for One Patient: Individualized Neoantigen Therapies
June 5, 2023
By: Michelle Brown, M.D., Ph.D., Program Leader, Oncology
Each person’s cancer is different because cancer cells have genetic mutations that make them unique, which can make the cancer difficult to treat. That's why we, in collaboration with Merck, are researching mRNA medicines that are designed specifically for an individual patient. Individualized neoantigen therapies (INTs) are an innovative approach that tailor treatment to each patient's individual cancer.
This week, we are participating in the American Society for Clinical Oncology (ASCO) Annual Meeting, where distant metastasis-free survival (DMFS) results from the Phase 2b study of our investigational mRNA individualized neoantigen therapy, mRNA-4157 (V940), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection, will be presented. The ASCO Annual Meeting is the world’s largest oncology conference, and we are honored to share these new data with the global oncology community.
We are incredibly grateful to the participants in our clinical trials and the investigators and clinical trial staff who are helping to advance this important cancer research.